964
On 22 March 2007, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 438. The active ingredient is Zanolimumab for treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated).